Stockscreener 앱 받기
8.76
6.05%
0.50
전일 마감가:
$8.26
열려 있는:
$8.5348
하루 거래량:
86,805
Relative Volume:
0.54
시가총액:
$163.83M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.79%
1개월 성능:
+48.85%
6개월 성능:
+235.63%
1년 성능:
+0.00%
1일 변동 폭
$8.40
$9.0907
1주일 범위
$7.915
$9.0907
52주 변동 폭
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
650-249-2727
주소
400 CONNELL DRIVE, BERKELEY HEIGHTS
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
8.76 | 154.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-11-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-07-23 | 재개 | Piper Sandler | Neutral |
| 2025-05-07 | 개시 | Leerink Partners | Outperform |
| 2025-04-08 | 개시 | William Blair | Outperform |
모두보기
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics raises $50M privately - MSN
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Expands By 26.1% - MarketBeat
Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS) - Defense World
Chardan Capital Initiates Coverage on Kalaris Therapeutics (NASDAQ:KLRS) - Defense World
Kalaris Therapeutics announces initial data from TH103 trial - MSN
Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat
Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq
Chardan Initiates Kalaris Therapeutics at Buy With $19 Price Target - marketscreener.com
Chardan Capital Markets initiates coverage on Kalaris stock with Buy rating - Investing.com Nigeria
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Why Kalaris Therapeutics Inc. stock is rated strong buyJuly 2025 Chart Watch & Real-Time Volume Triggers - Улправда
KLRS Kalaris Therapeutics Inc +8.76%eToro - eToro
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Kalaris Therapeutics Inc. stock is popular among millennialsJuly 2025 WrapUp & AI Powered Market Entry Strategies - Улправда
Will Kalaris Therapeutics Inc. stock deliver long term returnsJuly 2025 Momentum & Comprehensive Market Scan Reports - Улправда
Kalaris Therapeutics: Phase 1a Data De-Risks The Path To 2026 Catalysts (KLRS) - Seeking Alpha
Why retail investors pile into Kalaris Therapeutics Inc. stockLayoff News & Entry and Exit Point Strategies - DonanımHaber
Targets Report: Why Kalaris Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Smart Swing Trading Alerts - Улправда
Latham & Watkins Advises on Kalaris Therapeutics’ US$50 Million Private Placement - Legal Desire Media and Insights
Fundamentals Check: Will Kalaris Therapeutics Inc. stock outperform growth indexesJuly 2025 Reactions & Reliable Momentum Entry Alerts - Улправда
Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha
Kalaris stock price target raised to $26 at Citizens on TH103 data - Investing.com Canada
Kalaris Therapeutics Announces Oversubscribed $50 Million Financing - TipRanks
Kalaris Therapeutics Signs Multiple Material Agreements - TradingView — Track All Markets
Kalaris Therapeutics (NASDAQ: KLRS) lines up $50M private placement - Stock Titan
Kalaris Rises On Positive Early Data From Neovascular AMD Trial And $50Mln Financing Boost - Nasdaq
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD - The Manila Times
Kalaris reports positive early data for TH103 in AMD treatment By Investing.com - Investing.com Australia
Aspen Aerogels Announces Amendment to MidCap Credit Facility - The Manila Times
Vine Hill Capital Investment Corp. II Announces Pricing of Upsized $200 Million Initial Public Offering - The Manila Times
Future Mineral Announces Options Grant - The Manila Times
LACAHSA Board Approves $11.4M for Emergency Rental Assistance Funding, Bringing Total Measure A Prevention Investments to $29.5M in 2025 - The Manila Times
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement - The Manila Times
Biotech developing eye disease drug secures $50M to fund trials to 2027 - Stock Titan
Kalaris Posts Positive Results from Macular Degeneration Drug Trial - marketscreener.com
Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in nAMD - TradingView — Track All Markets
[8-K] Kalaris Therapeutics, Inc. Reports Material Event | KLRS SEC FilingForm 8-K - Stock Titan
Kalaris reports positive early data for TH103 in AMD treatment - Investing.com India
Kalaris Therapeutics reports positive initial Phase 1a data for TH103 - marketscreener.com
Single eye injection boosts vision in early test for macular degeneration - Stock Titan
Kalaris Therapeutics, Inc. announced that it expects to receive $49.99992 million in funding - marketscreener.com
Gold hits 5 week high – More gains aheadSector-Based Investing & Free Phenomenal Trading Returns - Bollywood Helpline
Kalaris Therapeutics Earnings Notes - Trefis
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) Biggest Owners Are Private Equity Firms Who Got Richer After Stock Soared 51% Last Week - 富途牛牛
Kalaris Therapeutics Inc Stock Analysis and ForecastPrice Volatility Patterns & Smarter Trades Backed by Machine Learning - earlytimes.in
Kalaris Therapeutics Inc. $KLRS Shares Sold by Gilead Sciences Inc. - MarketBeat
Top Gainers on the US Stock Market Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and More Surge as Fed Meeting Looms - ts2.tech
Is Kalaris Therapeutics Inc. stock a good choice for value investorsEarnings Beat & Verified High Yield Trade Plans - Newser
Kalaris Therapeutics (KLRS) Stock Analysis Report | Financials & Insights - Benzinga
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):